Synthesis, Anticancer Activity, and Apoptosis Induction of Novel 3,6-Diazaphenothiazines†
AbstractNew 10-substituted derivatives of 3,6-diazaphenothiazine, containing the triple bond linker terminated with tertiary cyclic and acyclic amine groups, were synthesized and screened for their anticancer action. The compounds exhibited varied anticancer activities against human glioblastoma SNB-19, melanoma C-32, and breast cancer MDA-MB231 cell lines, depending on the nature of the substituents. The most active 3,6-diazaphenothiazine, 4, was the derivative with the N,N-diethylamino-2-butynyl substituent against glioblastoma SNB-19, and was ten times more potent than cisplatin. For this compound, the expression of H3, TP53, CDKN1A, BCL-2, and BAX genes was detected by the RT-qPCR method. The gene expression ratio BAX/BCL-2 indicated the induction of mitochondrial apoptosis in cancer cell lines. The transformation of the propynyl substituent into amino-2-butynyl can be a method applicable to the search for more anticancer-active azaphenothiazines. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 330 KB)
Share & Cite This Article
Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Jeleń, M.; Kuśmierz, D. Synthesis, Anticancer Activity, and Apoptosis Induction of Novel 3,6-Diazaphenothiazines. Molecules 2019, 24, 267.
Morak-Młodawska B, Pluta K, Latocha M, Jeleń M, Kuśmierz D. Synthesis, Anticancer Activity, and Apoptosis Induction of Novel 3,6-Diazaphenothiazines. Molecules. 2019; 24(2):267.Chicago/Turabian Style
Morak-Młodawska, Beata; Pluta, Krystian; Latocha, Małgorzata; Jeleń, Małgorzata; Kuśmierz, Dariusz. 2019. "Synthesis, Anticancer Activity, and Apoptosis Induction of Novel 3,6-Diazaphenothiazines." Molecules 24, no. 2: 267.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.